Liraglutide Patent Expiration

Liraglutide is Used for improving glycemic control and reducing the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. It was first introduced by Novo Nordisk Inc in its drug Victoza on Jan 25, 2010. Another drug containing Liraglutide is Saxenda. 2 different companies have introduced drugs containing Liraglutide.


Liraglutide Patents

Given below is the list of patents protecting Liraglutide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Saxenda US9968659

(Pediatric)

Liraglutide in cardiovascular conditions Jul 09, 2037 Novo
Victoza US9968659

(Pediatric)

Liraglutide in cardiovascular conditions Jul 09, 2037 Novo Nordisk Inc
Saxenda US9968659 Liraglutide in cardiovascular conditions Jan 09, 2037 Novo
Victoza US9968659 Liraglutide in cardiovascular conditions Jan 09, 2037 Novo Nordisk Inc
Victoza US9265893

(Pediatric)

Injection button Mar 23, 2033 Novo Nordisk Inc
Victoza US9265893 Injection button Sep 23, 2032 Novo Nordisk Inc
Saxenda US9132239

(Pediatric)

Dial-down mechanism for wind-up pen Aug 01, 2032 Novo
Saxenda US9132239 Dial-down mechanism for wind-up pen Feb 01, 2032 Novo
Saxenda US9457154

(Pediatric)

Injection device with an end of dose feedback mechanism Mar 27, 2028 Novo
Saxenda US9457154 Injection device with an end of dose feedback mechanism Sep 27, 2027 Novo
Saxenda US9687611

(Pediatric)

Injection device with torsion spring and rotatable display Aug 27, 2027 Novo
Saxenda US9687611 Injection device with torsion spring and rotatable display Feb 27, 2027 Novo
Saxenda USRE46363

(Pediatric)

Dial-down mechanism for wind-up pen Feb 03, 2027 Novo
Saxenda US10220155

(Pediatric)

Syringe device with a dose limiting mechanism and an additional safety mechanism Jan 17, 2027 Novo
Saxenda US8920383

(Pediatric)

Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan 17, 2027 Novo
Saxenda US9775953

(Pediatric)

Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jan 17, 2027 Novo
Saxenda US7686786 Dial-down mechanism for wind-up pen Aug 03, 2026 Novo
Saxenda USRE46363 Dial-down mechanism for wind-up pen Aug 03, 2026 Novo
Saxenda US9108002

(Pediatric)

Automatic injection device with a top release mechanism Jul 26, 2026 Novo
Saxenda US9616180

(Pediatric)

Automatic injection device with a top release mechanism Jul 20, 2026 Novo
Saxenda US9861757

(Pediatric)

Injection device with an end of dose feedback mechanism Jul 20, 2026 Novo
Saxenda US10220155 Syringe device with a dose limiting mechanism and an additional safety mechanism Jul 17, 2026 Novo
Saxenda US11097063 Syringe device with a dose limiting mechanism and an additional safety mechanism Jul 17, 2026 Novo
Saxenda US8920383 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul 17, 2026 Novo
Saxenda US9775953 Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left Jul 17, 2026 Novo
Saxenda US8684969

(Pediatric)

Injection device with torsion spring and rotatable display Apr 20, 2026 Novo
Saxenda US8114833

(Pediatric)

Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb 13, 2026 Novo
Victoza US8114833

(Pediatric)

Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Feb 13, 2026 Novo Nordisk Inc
Saxenda US9108002 Automatic injection device with a top release mechanism Jan 26, 2026 Novo
Saxenda US10357616 Injection device with an end of dose feedback mechanism Jan 20, 2026 Novo
Saxenda US10376652 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Saxenda US11311679 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Saxenda US9616180 Automatic injection device with a top release mechanism Jan 20, 2026 Novo
Saxenda US9861757 Injection device with an end of dose feedback mechanism Jan 20, 2026 Novo
Saxenda US11446443 Injection device with torsion spring and rotatable display Oct 20, 2025 Novo
Saxenda US8684969 Injection device with torsion spring and rotatable display Oct 20, 2025 Novo
Saxenda US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug 13, 2025 Novo
Victoza US8114833 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices Aug 13, 2025 Novo Nordisk Inc
Saxenda US7762994

(Pediatric)

Needle mounting system and a method for mounting a needle assembly Nov 23, 2024

(Expired)

Novo
Victoza US7762994

(Pediatric)

Needle mounting system and a method for mounting a needle assembly Nov 23, 2024

(Expired)

Novo Nordisk Inc
Saxenda US7762994 Needle mounting system and a method for mounting a needle assembly May 23, 2024

(Expired)

Novo
Victoza US7762994 Needle mounting system and a method for mounting a needle assembly May 23, 2024

(Expired)

Novo Nordisk Inc
Saxenda US8579869

(Pediatric)

Needle mounting system and a method for mounting a needle assembly Dec 30, 2023

(Expired)

Novo
Victoza US8579869

(Pediatric)

Needle mounting system and a method for mounting a needle assembly Dec 30, 2023

(Expired)

Novo Nordisk Inc
Saxenda US8579869 Needle mounting system and a method for mounting a needle assembly Jun 30, 2023

(Expired)

Novo
Victoza US8579869 Needle mounting system and a method for mounting a needle assembly Jun 30, 2023

(Expired)

Novo Nordisk Inc
Saxenda US6268343

(Pediatric)

Derivatives of GLP-1 analogs Feb 22, 2023

(Expired)

Novo
Victoza US6268343

(Pediatric)

Derivatives of GLP-1 analogs Feb 22, 2023

(Expired)

Novo Nordisk Inc
Saxenda US8846618

(Pediatric)

Stable formulation of modified GLP-1 Dec 27, 2022

(Expired)

Novo
Victoza US8846618

(Pediatric)

Stable formulation of modified GLP-1 Dec 27, 2022

(Expired)

Novo Nordisk Inc
Saxenda US6268343 Derivatives of GLP-1 analogs Aug 22, 2022

(Expired)

Novo
Saxenda US8672898

(Pediatric)

Automatic injection device with reset feature Jul 02, 2022

(Expired)

Novo
Saxenda US9486588

(Pediatric)

Automatic injection device with reset feature Jul 02, 2022

(Expired)

Novo
Saxenda US6899699

(Pediatric)

Automatic injection device with reset feature Jul 01, 2022

(Expired)

Novo
Saxenda US8846618 Stable formulation of modified GLP-1 Jun 27, 2022

(Expired)

Novo
Victoza US8846618 Stable formulation of modified GLP-1 Jun 27, 2022

(Expired)

Novo Nordisk Inc
Saxenda US8672898 Automatic injection device with reset feature Jan 02, 2022

(Expired)

Novo
Saxenda US9486588 Automatic injection device with reset feature Jan 02, 2022

(Expired)

Novo
Saxenda US6899699 Automatic injection device with reset feature Jan 01, 2022

(Expired)

Novo
Victoza USRE41956

(Pediatric)

Dose setting limiter Jul 21, 2021

(Expired)

Novo Nordisk Inc
Victoza USRE41956 Dose setting limiter Jan 21, 2021

(Expired)

Novo Nordisk Inc
Victoza US6004297 Injection syringe Jan 28, 2019

(Expired)

Novo Nordisk Inc
Victoza USRE43834 Injection syringe Jan 28, 2019

(Expired)

Novo Nordisk Inc
Saxenda US6458924 Derivatives of GLP-1 analogs Aug 22, 2017

(Expired)

Novo
Saxenda US7235627 Derivatives of GLP-1 analogs Aug 22, 2017

(Expired)

Novo
Victoza US6268343 Derivatives of GLP-1 analogs Aug 22, 2017

(Expired)

Novo Nordisk Inc
Victoza US6458924 Derivatives of GLP-1 analogs Aug 22, 2017

(Expired)

Novo Nordisk Inc
Victoza US7235627 Derivatives of GLP-1 analogs Aug 22, 2017

(Expired)

Novo Nordisk Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Liraglutide's patents.

Given below is the list recent legal activities going on the following patents of Liraglutide.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 17 Feb, 2022 US8846618
Payment of Maintenance Fee, 4th Year, Large Entity 21 Oct, 2021 US9968659
Payment of Maintenance Fee, 12th Year, Large Entity 18 Oct, 2018 US7235627
Patent Issue Date Used in PTA Calculation 15 May, 2018 US9968659
Recordation of Patent Grant Mailed 15 May, 2018 US9968659
Email Notification 26 Apr, 2018 US9968659
Issue Notification Mailed 25 Apr, 2018 US9968659
Filing Receipt - Updated 13 Apr, 2018 US9968659
Dispatch to FDC 13 Apr, 2018 US9968659
Email Notification 13 Apr, 2018 US9968659


Liraglutide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Liraglutide News

Ozempic May Have Potential in Reducing Alcohol Dependence - Report from US News

13 Nov, 2024

Increased sales of Ozempic and Wegovy drive growth, along with the introduction of a generic weight loss drug by Hims - Yahoo

08 Nov, 2024

Nature explores how popular weight loss medications induce a sense of fullness before eating - a breakthrough in combating obesity.

27 Jun, 2024

Biocon plans to market a long-term weight management medication in Mexico, reports NDTV Profit.

13 May, 2024

See More